Granules India will hold a meeting of the Board of Directors of the Company on 15 May 2024.Powered by Capital Market - Live News

Granules India announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA), filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company, for Colchicine Capsules, 0.6 mg. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mitigare Capsules, 0.6 mg of Hikma International Pharmaceuticals LLC (Hikma).Colchicine Capsules are indicated for prophylaxis of gout flares in adults. Granules now have a total of 64 ANDA approvals from the US FDA (63 Final approvals and 1 tentative approvals).The current annual U.S. market for Colchicine Capsules is approximately $55 Million, according to MAT Feb 2024, IQVIA/IMS Health.Powered by Capital Market - Live News

Granules India has appointed Atul Dhavle as Chief Human Resources Officer (CHRO) of the Company with effect from today i.e. 11March 2024. Powered by Capital Market - Live News

The Board of Granules India has appointed Rajiv Pritidas Kakodkar (DIN: 01519590), as an Additional Director, categorized as Non-Executive Independent, on the Board of the Company with effect from 20 February 2024. Powered by Capital Market - Live News

The Board of Granules India has appointed Rajiv Pritidas Kakodkar (DIN: 01519590), as an Additional Director, categorized as Non-Executive Independent, on the Board of the Company with effect from 20 February 2024. Powered by Capital Market - Live News